They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.
They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.
Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.
Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.
Likes it. He hasn't bought it, because he isn't sure which stock to own in this sector. Abbott and Boston Scientific are better choices, he thinks, with more upside potential given product innovation.
Likes it. He hasn't bought it, because he isn't sure which stock to own in this sector. Abbott and Boston Scientific are better choices, he thinks, with more upside potential given product innovation.
Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N
In the last year, 16 stock analysts published opinions about SYK-N. 14 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Stryker Corp..
Stryker Corp. was recommended as a Top Pick by Paul Harris, CFA on 2020-12-24. Read the latest stock experts ratings for Stryker Corp..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
16 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.
On 2021-01-20, Stryker Corp. (SYK-N) stock closed at a price of $245.21.